SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Avacta Reports Faridoxorubicin Results in Salivary Gland Cancer

Avacta says faridoxorubicin treatment nearly doubled progression-free survival and produced clinically meaningful tumor shrinkage in most patients with salivary gland cancers.

AVACTA

Related stories